Krystal Biotech, Inc. (KRYS) Tops Q2 EPS by 7c, Beats on Revenue

Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q2 EPS of $1.29, $0.07 better than the analyst estimate of $1.22. Revenue for the quarter came in at $96.04 million versus the consensus estimate of $92.24 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.

You May Also Be Interested In

• Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance
• Cintas Corp. (CTAS) Tops Q1 EPS by 1c, Offers Guidance
• Bessent: agreed to extend China trade truce until January 10